Drug-associated renal dysfunction and injury

Han WK and Bonventre JV (2004) Biologic markers for the early detection of acute kidney injury. Curr Opin Crit Care 10: 476–482

Kleinknecht D et al. (1987) Drug-associated acute renal failure: a prospective collaborative study of 81 biopsied patients. Adv Exp Med Biol 212: 125–128

Kaloyandes GJ et al. (2001) Antibiotic and Immunosupression-Related Renal Failure. Philadelphia: Lippincott, Williams & Wilkins

Kleinknecht D (1995) Interstitial nephritis, the nephrotic syndrome, and chronic renal failure secondary to nonsteroidal anti-inflammatory drugs. Semin Nephrol 15: 228–235

Klinkhoff AV and Teufel A (1997) Reinstitution of gold after gold induced proteinuria. J Rheumatol 24: 1277–1279

Wilcox CS (1999) Metabolic and adverse effects of diuretics. Semin Nephrol 19: 557–568

Ellison DH (2001) Diuretic therapy and resistance in congestive heart failure. Cardiology 96: 132–143

Fliser D (1996) Loop diuretics and thiazides—the case for their combination in chronic renal failure. Nephrol Dial Transplant 11: 408–410

Sandhofer A et al. (2002) Severe electrolyte disturbances and renal failure in elderly patients with combined diuretic therapy including xipamid. Wien Klin Wochenschr 114: 938–942

Suki WN (1997) Use of diuretics in chronic renal failure. Kidney Int 59 (Suppl): S33–S35

Cruz J et al. (2004) Successful use of the new high-dose mannitol treatment in patients with Glasgow Coma Scale scores of 3 and bilateral abnormal pupillary widening: a randomized trial. J Neurosurg 100: 376–383

Ejaz P et al. (2004) NSAIDs and kidney. J Assoc Physicians India 52: 632–640

Nankivell BJ et al. (2004) Oral cyclosporine but not tacrolimus reduces renal transplant blood flow. Transplantation 77: 1457–1459

Olyaei AJ et al. (2001) Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies. Curr Opin Crit Care 7: 384–389

Fang LS et al. (1980) Low fractional excretion of sodium with contrast media-induced acute renal failure. Arch Intern Med 140: 531–533

Van Buren D et al. (1985) De novo hemolytic uremic syndrome in renal transplant recipients immunosuppressed with cyclosporine. Surgery 98: 54–62

Bren A et al. (2005) Follow-up of kidney graft recipients with cyclosporine-associated hemolytic-uremic syndrome and thrombotic microangiopathy. Transplant Proc 37: 1889–1891

Abraham KA et al. (2000) Hemolytic–uremic syndrome in association with both cyclosporine and tacrolimus. Transpl Int 13: 443–447

Lin CC et al. (2003) Tacrolimus-associated hemolytic uremic syndrome: a case analysis. J Nephrol 16: 580–585

Abramowicz D et al. (1992) Induction of thromboses within renal grafts by high-dose prophylactic OKT3. Lancet 339: 777–778

Medina PJ et al. (2001) Drug-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Curr Opin Hematol 8: 286–293

Chinnakotla S et al. (2000) Clopidogrel-associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome in a kidney/pancreas transplant recipient. Transplantation 70: 550–552

Izzedine H et al. (2005) Antiviral drug-induced nephrotoxicity. Am J Kidney Dis 45: 804–817

Jackson AM et al. (1984) Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy. Ann Intern Med 101: 41–44

Giroux L et al. (1985) Mitomycin-C nephrotoxicity: a clinico-pathologic study of 17 cases. Am J Kidney Dis 6: 28–39

Pisoni R et al. (2001) Drug-induced thrombotic microangiopathy: incidence, prevention and management. Drug Saf 24: 491–501

Venkat KK et al. (1991) Reversal of cyclosporine-associated hemolytic–uremic syndrome by plasma exchange with fresh-frozen plasma replacement in renal transplant recipients. Transplant Proc 23: 1256–1257

Trimarchi HM et al. (1999) FK506-associated thrombotic microangiopathy: report of two cases and review of the literature. Transplantation 67: 539–544

Price TM et al. (1985) Renal failure and hemolytic anemia associated with mitomycin C. A case report. Cancer 55: 51–56

Garibotto G et al. (1989) Successful treatment of mitomycin C-associated hemolytic uremic syndrome by plasmapheresis. Nephron 51: 409–412

Ponticelli C et al. (1977) Late recovery of renal function in a woman with the hemolytic uremic syndrome. Clin Nephrol 8: 367–370

Hauglustaine D et al. (1981) Oestrogen containing oral contraceptives, decreased prostacyclin production, and haemolytic uraemic syndrome. Lancet 1: 328–329

Ruggenenti P and Remuzzi G (1990) Thrombotic thrombocytopenic purpura and related disorders. Hematol Oncol Clin North Am 4: 219–241

Berns JS et al. (1992) Inherited hemolytic uremic syndrome in adults. Am J Kidney Dis 19: 331–334

Kintzel PE (2001) Anticancer drug-induced kidney disorders. Drug Saf 24: 19–38

Walter RB et al. (2002) Gemcitabine-associated hemolytic–uremic syndrome. Am J Kidney Dis 40: E16

Hitti WA and Anderson J (2005) Cholesterol emboli-induced renal failure and gastric ulcer after thrombolytic therapy. South Med J 98: 235–237

Ben-Chitrit S et al. (1994) Cholesterol embolization syndrome following thrombolytic therapy with streptokinase and tissue plasminogen activator. Nephrol Dial Transplant 9: 428–430

Eliot RS et al. (1964) Atheromatous Embolism. Circulation 30: 611–618

Pennington M et al. (2002) Cholesterol embolization syndrome: cutaneous histopathological features and the variable onset of symptoms in patients with different risk factors. Br J Dermatol 146: 511–517

Fine MJ et al. (1987) Cholesterol crystal embolization: a review of 221 cases in the English literature. Angiology 38: 769–784

Lameire N et al. (2005) Acute renal failure. Lancet 365: 417–430

Edelstein CL and Schrier R (2001) Pathophysiology of Ischemic Acute Renal Injury. Philadelphia: Lippincott, Williams & Wilkins

Henrich WL (2005) Nephrotoxicity of several newer agents. Kidney Int 67 (Suppl): S107–S109

Ho ES et al. (2000) Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1. J Am Soc Nephrol 11: 383–393

Nagai J and Takano M (2004) Molecular aspects of renal handling of aminoglycosides and strategies for preventing the nephrotoxicity. Drug Metab Pharmacokinet 19: 159–170

Kaloyanides GJ and Pastoriza-Munoz E (1980) Aminoglycoside nephrotoxicity. Kidney Int 18: 571–582

Cronin RE and Henrich WL (1996) Toxic Nephropathy. Philadelphia: WB Saunders

Maher J (1991) Toxic Nephropathies. Boston: Kluwer Academic Publishers

Patel R and Savage A (1979) Symptomatic hypomagnesemia associated with gentamicin therapy. Nephron 23: 50–52

Taguchi T et al. (2005) Cisplatin-associated nephrotoxicity and pathological events. Contrib Nephrol 148: 107–121

Uehara T et al. (2005) Nephrotoxicity of a novel antineoplastic platinum complex, nedaplatin: a comparative study with cisplatin in rats. Arch Toxicol 79: 451–460

Markowitz GS et al. (2003) Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 64: 281–289

Hiroi-Furuya E et al. (1999) Etidronate (EHDP) inhibits osteoclastic-bone resorption, promotes apoptosis and disrupts actin rings in isolate-mature osteoclasts. Calcif Tissue Int 64: 219–223

Markowitz G et al. (2001) Collapsing focal segmental glomerulosclerosis following treatment with high dose pamidronate. J Am Soc Nephrol 12: 1164–1172

Orbach H et al. (2004) Intravenous immunoglobulin and the kidney—a two-edged sword. Semin Arthritis Rheum 34: 593–601

Khalil M et al. (2000) Macrophagelike vacuolated renal tubular cells in the urine of a male with osmotic nephrosis associated with intravenous immunoglobulin therapy: a case report. Acta Cytol 44: 86–90

Visweswaran P et al. (1997) Mannitol-induced acute renal failure. J Am Soc Nephrol 8: 1028–1033

Ferraboli R et al. (1997) Anuric acute renal failure caused by dextran 40 administration. Ren Fail 19: 303–306

Erdbruegger U et al. (2004) Quiz page: tubular epithelial injury consistent with osmotic nephrosis. Am J Kidney Dis 44: e1

De Labarthe A et al. (2001) Acute renal failure secondary to hydroxyethylstarch administration in a surgical patient. Am J Med 111: 417–418

Hansen-Schmidt S et al. (1996) Osmotic nephrosis due to high-dose immunoglobulin therapy containing sucrose (but not with glycine) in a patient with immunoglobulin A nephritis. Am J Kidney Dis 28: 451–453

Gossmann J et al. (2001) Pathophysiology of cyclosporine-induced nephrotoxicity in humans: a role for nitric oxide? Kidney Blood Press Res 24: 111–115

Andoh TF et al. (1996) Comparison of acute rapamycin nephrotoxicity with cyclosporine and FK506. Kidney Int 50: 1110–1117

Gibbs WJ et al. (2005) Liposomal amphotericin B: clinical experience and perspectives. Expert Rev Anti Infect Ther 3: 167–181

Porter GA (1989) Contrast-associated nephropathy. Am J Cardiol 64: 22E–26E

Mueller C et al. (2002) Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med 162: 329–336

Briguori C et al. (2005) New pharmacological protocols to prevent or reduce contrast media nephropathy. Minerva Cardioangiol 53: 49–58

Tepel M et al. (2000) Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 343: 180–184

Stone GW et al. (2003) Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. JAMA 290: 2284–2291

Vogt B et al. (2001) Prophylactic hemodialysis after radiocontrast media in patients with renal insufficiency is potentially harmful. Am J Med 111: 692–698

Marenzi G et al. (2003) The prevention of radiocontrast-agent-induced nephropathy by hemofiltration. N Engl J Med 349: 1333–1340

Kancha K et al. (2004) Hemofiltration and the prevention of radiocontrast-agent-induced nephropathy. N Engl J Med 350: 836–838; author reply 836–838

Forman JP (2004) Hemofiltration and the prevention of radiocontrast-agent-induced nephropathy. N Engl J Med 350: 836–838; author reply 836–838

Sam AD II et al. (2003) Safety of gadolinium contrast angiography in patients with chronic renal insufficiency. J Vasc Surg 38: 313–318

Rossert J (2001) Drug-induced acute interstitial nephritis. Kidney Int 60: 804–817

Baylor P and Williams K (1999) Interstitial nephritis, thrombocytopenia, hepatitis, and elevated serum amylase levels in a patient receiving clarithromycin therapy. Clin Infect Dis 29: 1350–1351

Tintillier M et al. (2004) Telithromycin-induced acute interstitial nephritis: a first case report. Am J Kidney Dis 44: e25–e27

Szalat A et al. (2004) Acute renal failure and interstitial nephritis in a patient treated with rofecoxib: case report and review of the literature. Arthritis Rheum 51: 670–673

Ra A and Tobe SW (2004) Acute interstitial nephritis due to pantoprazole. Ann Pharmacother 38: 41–45

Clarkson MR et al. (2004) Acute interstitial nephritis: clinical features and response to corticosteroid therapy. Nephrol Dial Transplant 19: 2778–2783

Clive DM and Stoff JS (1984) Renal syndromes associated with nonsteroidal antiinflammatory drugs. N Engl J Med 310: 563–572

Hanabusa H et al. (1999) Renal atrophy associated with long-term treatment with indinavir. N Engl J Med 340: 392–393

Martinez F et al. (1998) Indinavir crystal deposits associated with tubulointerstitial nephropathy. Nephrol Dial Transplant 13: 750–753

Daudon M and Jungers P (2004) Drug-induced renal calculi: epidemiology, prevention and management. Drugs 64: 245–275

Demko TM et al. (1997) Obstructive nephropathy as a result of retroperitoneal fibrosis: a review of its pathogenesis and associations. J Am Soc Nephrol 8: 684–688

Waters VV (1989) Hydralazine, hydrochlorothiazide and ampicillin associated with retroperitoneal fibrosis: case report. J Urol 141: 936–937

Iversen BM et al. (1975) Retroperitoneal fibrosis during treatment with methydopa. Lancet 2: 302–304

Damstrup L and Jensen TT (1986) Retroperitoneal fibrosis after long-term daily use of ergotamine. Int Urol Nephrol 18: 299–301

Perneger TV et al. (1994) Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs. N Engl J Med 331: 1675–1679

Nanra RS et al. (1978) Analgesic nephropathy: etiology, clinical syndrome, and clinicopathologic correlations in Australia. Kidney Int 13: 79–92

Gloor FJ (1978) Changing concepts in pathogenesis and morphology of analgesic nephropathy as seen in Europe. Kidney Int 13: 27–33

Kincaid-Smith P (1980) Analgesic abuse and the kidney. Kidney Int 17: 250–260

Bach PH and Hardy TL (1985) Relevance of animal models to analgesic-associated renal papillary necrosis in humans. Kidney Int 28: 605–613

Akhund L et al. (2003) Celecoxib-related renal papillary necrosis. Arch Intern Med 163: 114–115

Blohme I and Johansson S (1981) Renal pelvic neoplasms and atypical urothelium in patients with end-stage analgesic nephropathy. Kidney Int 20: 671–675

McCredie M et al. (1986) Phenacetin and papillary necrosis: independent risk factors for renal pelvic cancer. Kidney Int 30: 81–84

Busauschina A et al. (2004) Cyclosporine nephrotoxicity. Transplant Proc 36: 229S–233S

Markowitz GS et al. (2000) Lithium nephrotoxicity: a progressive combined glomerular and tubulointerstitial nephropathy. J Am Soc Nephrol 11: 1439–1448

Rojek A et al. (2005) Altered expression of selected genes in kidney of rats with lithium-induced NDI. Am J Physiol Renal Physiol 288: F1276–1289

Cutting HO (1971) Inappropriate secretion of antidiuretic hormone secondary to vincristine therapy. Am J Med 51: 269–271

Steele TH et al. (1973) Antidiuretic response to cyclophosphamide in man. J Pharmacol Exp Ther 185: 245–253

Edwards OM et al. (1970) Azotaemia aggravated by tetracycline. Br Med J 1: 26–27